Investments in progress
We are currently investing in one or more companies that passed our rigorous selection process. Please login or create an account to learn more and co-invest with us.
Our portfolio companies
Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
Encare AB
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
Capitainer AB
Capitainer offers a unique platform for the self-sampling of fingertip blood and plasma based on a patented microfluidic technology. The products enable easy home sampling with high precision, delivering value across the entire care chain.
Akiram Therapeutics
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Pharmnovo AB
PharmNovo develops a novel drug for nerve pain, where there is a high, unmet need for effective and safe treatments. The candidate PN6047 shows effective pain relief in animal models, without the negative side effects associated with existing drugs.
Exits
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Inhalation Sciences
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
Read more
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
Read more